Investigating Drug Resistance in Prostate Cancer

The Lab Rats
Cammy Kutter, Ethan Cohen,
and Sai Manikonda

Challenge Question

Can we identify druggable genes and pathways that contribute to enzalutamide resistance?



Rodriguez-Vida et al. 2015. https://doi.org/10.2147/DDDT.S69433

Prostate Cancer Data Exploration

Estimated New Cases

Males			Females		
Prostate	288,300	29%	Breast	297,790	31%
Lung & bronchus	117,550	12%	Lung & bronchus	120,790	13%
Colon & rectum	81,860	8%	Colon & rectum	71,160	8%
Urinary bladder	62,420	6%	Uterine corpus	66,200	7%
Melanoma of the skin	58,120	6%	Melanoma of the skin	39,490	4%
Kidney & renal pelvis	52,360	5%	Non-Hodgkin lymphoma	35,670	4%
Non-Hodgkin lymphoma	44,880	4%	Thyroid	31,180	3%
Oral cavity & pharynx	39,290	4%	Pancreas	30,920	3%
Leukemia	35,670	4%	Kidney & renal pelvis	29,440	3%
Pancreas	33,130	3%	Leukemia	23,940	3%
All Sites	**1,010,310**	**100%**	**All Sites**	**948,000**	**100%**

Estimated Deaths

Males			Females		
Lung & bronchus	67,160	21%	Lung & bronchus	59,910	21%
Prostate	34,700	11%	Breast	43,170	15%
Colon & rectum	28,470	9%	Colon & rectum	24,080	8%
Pancreas	26,620	8%	Pancreas	23,930	8%
Liver & intrahepatic bile duct	19,000	6%	Ovary	13,270	5%
Leukemia	13,900	4%	Uterine corpus	13,030	5%
Esophagus	12,920	4%	Liver & intrahepatic bile duct	10,380	4%
Urinary bladder	12,160	4%	Leukemia	9,810	3%
Non-Hodgkin lymphoma	11,780	4%	Non-Hodgkin lymphoma	8,400	3%
Brain & other nervous system	11,020	3%	Brain & other nervous system	7,970	3%
All Sites	**322,080**	**100%**	**All Sites**	**287,740**	**100%**



Data Production Experimental Design



Verifying differences between the conditions with PCA



Differential Expression Analysis Reveals Druggable Genes



How can we use previously collected data to as motivation for new experimentation?

- Identify enriched pathways
- Narrow focus to one pathway
- Investigate the mechanisms of the chosen path





Data on KEGG graph
Rendered by Pathview

Experimental Design



Advantages and Disadvantages of our Approach



References

- Denmeade SR, Isaacs JT. A history of prostate cancer treatment. Nat Rev Cancer. 2002 May;2(5):389-96. doi: 10.1038/nrc801. PMID: 12044015; PMCID: PMC4124639.
- Kobayashi, Y., Iwakura, Y., Sotoyama, H. et al. Clozapine-dependent inhibition of EGF/neuregulin receptor (ErbB) kinases. Transl Psychiatry 9, 181 (2019). https://doi.org/10.1038/s41398-019-0519-1
- Lowder D, Rizwan K, McColl C, Paparella A, Ittmann M, Mitsiades N, Kaochar S. Racial disparities in prostate cancer: A complex interplay between socioeconomic inequities and genomics. Cancer Lett. 2022 Apr 10;531:71-82. doi: 10.1016/j.canlet.2022.01.028. Epub 2022 Feb 3. PMID: 35122875; PMCID: PMC9701576.
- Siegel, RL, Miller, KD, Wagle, NS, Jemal, A. Cancer statistics, 2023. CA Cancer J Clin. 2023; 73(1): 17-48. doi:10.3322/caac.21763\
- https://www.selleckchem.com/products/pf299804.html

Data and Code Availability: https://github.com/saipra003/mini-dream_nci_dcb_summer_2023

Questions?